Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF‐κB in lung cancer and in normal pulmonary tissues. (19th March 2013)

• Record Type: Journal Article
• Authors: Falcone, D.; Gallelli, L.; Di Virgilio, A.; Tucci, L.; Scaramuzzino, M.; Terracciano, R.; Pelaia, G.; Savino, R.
• Is Part Of: Cell proliferation. Volume 46:Number 2(2013:Apr.)
• Page Start: 172
• Page End: 182
• Publication Date: 2013-03-19
• Subjects: Cell proliferation -- Periodicals; 571.84
• DOI: 10.1111/cpr.12018
• Languages: English
• ISSNs: 0960-7722

Abstract

<abstract abstract-type="main" xml:lang="en" id="cpr12018-abs-0001"> <title>Abstract</title> <sec id="cpr12018-sec-0001" sec-type="section"> <title>Objectives</title> <p>In this study, we have evaluated effects of 24‐hour treatments with simvastatin or rosuvastatin on RAS protein, NF‐κB and MMP expression in LC tissues obtained from 12 patients undergoing thoracic surgery.</p> </sec> <sec id="cpr12018-sec-0002" sec-type="section"> <title>Materials and methods</title> <p>Normal and lung tumour tissues obtained from each sample were exposed to simvastatin (2.5–30 μ<sc>m</sc>) or rosuvastatin (1.25–30 μ<sc>m</sc>) and western blot analysis was then performed.</p> </sec> <sec id="cpr12018-sec-0003" sec-type="section"> <title>Results</title> <p>We documented increased expression of proteins, MMP‐2, MMP‐9 and NF‐κB‐p65 in LC tissues, with respect to normal tissues (<italic>P</italic> &lt; 0.01). In the malignant tissues, simvastatin and rosuvastatin significantly (<italic>P</italic> &lt; 0.01) and dose‐dependently reduced RAS protein, MMP‐2/9 and NF‐κB‐p65 expression.</p> </sec> <sec id="cpr12018-sec-0004" sec-type="section"> <title>Conclusions</title> <p>In conclusion, our results suggest that simvastatin and rosuvastatin could play a role in LC treatment by modulation of RAS protein, MMP‐2/9 and NF‐κB‐p65.</p> </sec> </abstract>